Cingulate (NASDAQ:CING) CEO Shane Schaffer Buys 6,809 Shares

Cingulate Inc. (NASDAQ:CING) CEO Shane Schaffer bought 6,809 shares of the company’s stock in a transaction on Friday, February 6th. The shares were acquired at an average price of $5.04 per share, for a total transaction of $34,317.36. Following the transaction, the chief executive officer directly owned 10,175 shares in the company, valued at $51,282. This trade represents a 202.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Cingulate Price Performance

CING opened at $6.82 on Wednesday. Cingulate Inc. has a 12 month low of $3.20 and a 12 month high of $7.92. The stock has a market capitalization of $50.81 million, a P/E ratio of -1.88 and a beta of -0.75. The business has a 50 day simple moving average of $4.92 and a 200-day simple moving average of $4.30.

Cingulate (NASDAQ:CING) last released its earnings results on Thursday, November 13th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.55). Research analysts anticipate that Cingulate Inc. will post -11.69 EPS for the current year.

Institutional Trading of Cingulate

Several institutional investors and hedge funds have recently modified their holdings of CING. Bank of America Corp DE increased its stake in shares of Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after purchasing an additional 5,543 shares in the last quarter. Soltis Investment Advisors LLC purchased a new stake in Cingulate in the 4th quarter valued at approximately $43,000. XTX Topco Ltd acquired a new stake in Cingulate during the 2nd quarter valued at $45,000. Quantum Private Wealth LLC increased its position in Cingulate by 140.0% during the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock worth $94,000 after buying an additional 14,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Cingulate by 43.9% in the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after acquiring an additional 18,629 shares during the last quarter. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CING shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cingulate in a report on Wednesday, January 21st. Roth Mkm decreased their price target on Cingulate from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Finally, Ascendiant Capital Markets dropped their price objective on Cingulate from $62.00 to $58.00 and set a “buy” rating for the company in a research note on Monday, December 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.33.

Cingulate News Summary

Here are the key news stories impacting Cingulate this week:

• Positive Sentiment: Company insiders (CEO Shane J. Schaffer) bought 6,809 shares at ~$5.04 on Feb 6, increasing his stake >200% — a strong vote of confidence from management. Read More.
• Positive Sentiment: CFO Jennifer L. Callahan purchased 4,864 shares at ~$5.04 on Feb 6, substantially raising her position — another management buy that can be viewed as bullish. Read More.
• Positive Sentiment: EVP Matthew Brams bought 1,946 shares at ~$5.04 on Feb 6, increasing his ownership by ~72% — additional insider accumulation. Read More.
• Positive Sentiment: Director Peter J. Werth acquired 19,455 shares at ~$5.04 on Feb 6, a ~20% increase in his stake — significant dollar-sized insider purchase. Read More.
• Neutral Sentiment: A new study reports impaired brain energy metabolism in people with post-COVID — relevant to long-COVID neuroscience but only indirectly related to Cingulate unless the company ties its programs to this biology. Read More.
• Neutral Sentiment: On Feb 10 a short-interest data point shows “0 shares” (an apparent reporting glitch), which creates temporary data uncertainty for traders; treat with caution.
• Negative Sentiment: Earlier short-interest (Jan 30) rose to 389,923 shares — ~5.5% of float and a short‑ratio near 1 day — indicating active short-selling pressure that can amplify downward moves.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.